AgResearch Ltd, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand.
Molecular Epidemiology and Public Health Laboratory, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
PLoS One. 2024 Jan 5;19(1):e0296290. doi: 10.1371/journal.pone.0296290. eCollection 2024.
Antimicrobial resistance is a global threat to human and animal health, with the misuse and overuse of antimicrobials suggested as the main drivers of resistance. Antimicrobial therapy can alter the bacterial community composition and the faecal resistome in cattle. Little is known about the impact of systemic antimicrobial therapy on the faecal microbiome in dairy cows in the presence of disease. Therefore, this study aimed to assess the impact of systemic antimicrobial therapy on the faecal microbiome in dairy cows in the pastoral farm environment, by analysing faecal samples from cattle impacted by several different clinically-defined conditions and corresponding antimicrobial treatments. Analysis at the individual animal level showed a decrease in bacterial diversity and richness during antimicrobial treatment but, in many cases, the microbiome diversity recovered post-treatment when the cow re-entered the milking herd. Perturbations in the microbiome composition and the ability of the microbiome to recover were specific at the individual animal level, highlighting that the animal is the main driver of variation. Other factors such as disease severity, the type and duration of antimicrobial treatment and changes in environmental factors may also impact the bovine faecal microbiome. AmpC-producing Escherichia coli were isolated from faeces collected during and post-treatment with ceftiofur from one cow while no third-generation cephalosporin resistant E. coli were isolated from the untreated cow samples. This isolation of genetically similar plasmid-mediated AmpC-producing E. coli has implications for the development and dissemination of antibiotic resistant bacteria and supports the reduction in the use of critically important antimicrobials.
抗微生物药物耐药性是对人类和动物健康的全球性威胁,抗微生物药物的滥用和过度使用被认为是耐药性的主要驱动因素。抗微生物治疗可以改变牛的细菌群落组成和粪便耐药组。在存在疾病的情况下,关于系统使用抗微生物药物治疗对奶牛粪便微生物组的影响知之甚少。因此,本研究旨在通过分析受多种不同临床定义条件和相应抗微生物治疗影响的牛的粪便样本,评估系统使用抗微生物药物治疗对牧场环境中奶牛粪便微生物组的影响。在个体动物水平上的分析表明,在抗微生物治疗期间细菌多样性和丰富度下降,但在许多情况下,当奶牛重新进入挤奶群时,微生物组的多样性在治疗后恢复。微生物组组成的扰动和微生物组恢复的能力在个体动物水平上是特异性的,这突出表明动物是变异的主要驱动因素。其他因素,如疾病严重程度、抗微生物治疗的类型和持续时间以及环境因素的变化,也可能影响牛的粪便微生物组。从一头牛在使用头孢噻呋治疗期间和之后收集的粪便中分离出了产 AmpC 型大肠埃希菌,而未从未接受治疗的牛样中分离出第三代头孢菌素耐药的大肠埃希菌。这种遗传上相似的质粒介导的产 AmpC 型大肠埃希菌的分离对抗生素耐药细菌的产生和传播具有影响,并支持减少关键重要抗微生物药物的使用。